What new 'moonshots' is Pfizer pursuing under CEO Albert Bourla?

CEO Albert Bourla is directing Pfizer's focus towards developing revolutionary drugs, specifically mentioning GLP-1s and advancing cancer treatments.

What leadership lessons does Albert Bourla emphasize?

Albert Bourla emphasizes resilience, stating that winners are differentiated by their ability to always stand up again after falling.

Home / Business and Economy / Pfizer CEO: Rising Again After COVID Heights

Pfizer CEO: Rising Again After COVID Heights

Q: What is Pfizer's current revenue situation post-COVID?

Pfizer's COVID-related revenue has significantly decreased from over $56 billion in 2022 to approximately $5 billion as of 2026-01-27T13:31:32+00:00, leading to a 'patent cliff' challenge.

27 Jan

•

Summary

Pfizer's COVID-related revenue dropped significantly from $56 billion to $5 billion.
CEO Albert Bourla is targeting revolutionary drugs like GLP-1s and cancer treatments.
Bourla emphasizes resilience, stating winners always stand up again after falling.

Pfizer CEO: Rising Again After COVID Heights

Pfizer CEO Albert Bourla is leading the pharmaceutical giant through a significant post-pandemic transition. After achieving record revenues driven by COVID-19 products, including the first FDA-approved vaccine and Paxlovid, the company faces substantial financial challenges. COVID-related revenue has plummeted from over $56 billion in 2022 to approximately $5 billion as of 2026-01-27T13:31:32+00:00. This financial downturn, termed a 'patent cliff,' necessitates a strategic shift.

Bourla, drawing on his experience and a philosophy of resilience, is positioning Pfizer for new ambitious goals. The company is investing in the development of revolutionary drugs, including GLP-1s, and is focused on transforming cancer treatment. He believes that determination and the ability to recover from setbacks are key to sustained success.